Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale.
Terrenato I, Arena V, Pizzamiglio S, Pennacchia I, Perracchio L, Buglioni S, Ercolani C, Sperati F, Costarelli L, Bonanno E, Baldini D, Candia S, Crescenzi A, Dal Mas A, Di Cristofano C, Gomes V, Grillo LR, Pasquini P, Pericoli MN, Ramieri MT, Di Stefano D, Ruco L, Scarpino S, Vitolo D, d'Amati G, Paradiso A, Verderio P, Mottolese M. Terrenato I, et al. Among authors: mottolese m. J Exp Clin Cancer Res. 2013 Aug 21;32(1):58. doi: 10.1186/1756-9966-32-58. J Exp Clin Cancer Res. 2013. PMID: 23965490 Free PMC article.
Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.
Ercolani C, Marchiò C, Di Benedetto A, Fabi A, Perracchio L, Vici P, Sperati F, Buglioni S, Arena V, Pescarmona E, Sapino A, Terrenato I, Mottolese M. Ercolani C, et al. Among authors: mottolese m. J Exp Clin Cancer Res. 2017 Oct 13;36(1):143. doi: 10.1186/s13046-017-0613-2. J Exp Clin Cancer Res. 2017. PMID: 29029640 Free PMC article.
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.
Fabi A, Di Benedetto A, Metro G, Perracchio L, Nisticò C, Di Filippo F, Ercolani C, Ferretti G, Melucci E, Buglioni S, Sperduti I, Papaldo P, Cognetti F, Mottolese M. Fabi A, et al. Among authors: mottolese m. Clin Cancer Res. 2011 Apr 1;17(7):2055-64. doi: 10.1158/1078-0432.CCR-10-1920. Epub 2011 Feb 9. Clin Cancer Res. 2011. PMID: 21307144
The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.
Vici P, Mottolese M, Pizzuti L, Barba M, Sperati F, Terrenato I, Di Benedetto A, Natoli C, Gamucci T, Angelucci D, Ramieri MT, Di Lauro L, Sergi D, Bartucci M, Dattilo R, Pagliuca A, De Maria R, Maugeri-Saccà M. Vici P, et al. Among authors: mottolese m. Oncotarget. 2014 Oct 30;5(20):9619-25. doi: 10.18632/oncotarget.2449. Oncotarget. 2014. PMID: 25294813 Free PMC article. Clinical Trial.
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Vici P, Ercolani C, Di Benedetto A, Pizzuti L, Di Lauro L, Sperati F, Terrenato I, Gamucci T, Natoli C, Di Filippo F, Botti C, Barba M, Mottolese M, De Maria R, Maugeri-Saccà M. Vici P, et al. Among authors: mottolese m. J Exp Clin Cancer Res. 2016 Apr 2;35:62. doi: 10.1186/s13046-016-0338-7. J Exp Clin Cancer Res. 2016. PMID: 27039292 Free PMC article.
Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy.
Ercolani C, Di Benedetto A, Terrenato I, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Buglioni S, Ramieri MT, Mentuccia L, Gamucci T, Perracchio L, Pescarmona E, Mottolese M, Barba M, Vici P, De Maria R, Maugeri-Saccà M. Ercolani C, et al. Among authors: mottolese m. Cancer Biol Ther. 2017 May 4;18(5):339-346. doi: 10.1080/15384047.2017.1312230. Epub 2017 Apr 7. Cancer Biol Ther. 2017. PMID: 28387539 Free PMC article.
p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study.
Fabi A, Mottolese M, Di Benedetto A, Sperati F, Ercolani C, Buglioni S, Nisticò C, Ferretti G, Vici P, Perracchio L, Malaguti P, Russillo M, Botti C, Pescarmona E, Cognetti F, Terrenato I. Fabi A, et al. Among authors: mottolese m. Clin Breast Cancer. 2020 Dec;20(6):e761-e770. doi: 10.1016/j.clbc.2020.05.005. Epub 2020 May 13. Clin Breast Cancer. 2020. PMID: 32580907
243 results